• About
    • Overview
    • Team
    • Contact
  • Our Science
    • About Epigenetics
    • Our Approach
    • Therapeutic Applications
  • Our Programs
    • Pipeline
    • BET
    • EZH2
    • LSD1
    • Preclinical
    • Expanded Access
    • Publications
  • Careers
    • Company Culture
    • Core Values
    • Benefits
    • Join Us
  • Investors & Media
    • Investor Overview
    • Stock Information
    • News & Events
    • Financial Information
    • Corporate Governance
    • Investor Resources
Publications & Presentations
  • 1/26/2021Identification and characterization of 2nd generation EZH2 inhibitors with extended residence times and improved biological activity
  • 5/6/2020Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors
  • 4/13/2020Merkel Cell Polyomavirus Activates LSD1-Mediated Blockade of Non-Canonical BAF to Regulate Transformation and Tumorigenesis
  • 3/26/2020Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time
  • 6/3/2019A Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Protein Inhibitor (BETi) Alone or With Ruxolitinib (RUX) in Patients with Myelofibrosis (MF)
  • 5/16/2019CPI-0610, a Bromodomain and Extraterminal Domain (BET) Inhibitor, Reduces Pro-Inflammatory Cytokines, Bone Marrow Fibrosis and the Number of Transfusions in …
  • 5/15/2019A Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Protein Inhibitor (BETi) alone or with Ruxolitinib (RUX), in Patients with Myelofibrosis (MF)
  • 4/2/2019Single-cell RNA sequencing reveals transcriptomic heterogeneity in response to epigenetic inhibitors
  • 4/1/2019ProSTAR: A phase 1b/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic …
  • 11/16/2018EZH2 inhibition as an effective treatment for metastatic castration-resistant prostate cancer
  • 11/22/2016An alternative approach to ChIP-Seq normalization enables detection of genome-wide changes in histone H3 lysine 27 trimethylation upon EZH2 inhibition
  • 10/10/2016Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide …
  • 04/05/2016Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes
  • 03/15/2016Preclinical anticancer efficacy of BET bromodomain inhibitors is determined by the apoptotic response
  • 02/25/2016Identification of a benzoisoxazoloazepine inhibitor (CPI-0610) of the bromodomain and extra-terminal (BET) family as a candidate for human clinical trials
  • 04/17/2015Development of methyl isoxazoleazepines as inhibitors of BET
  • 03/25/2015Discovery of benzotriazolo[4,3-d][1,4]diazepines as orally active inhibitors of BET bromodomains
  • 12/16/2014The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors
  • 12/16/2014Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
  • 11/14/2014EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation
  • 09/05/2014A Practical Synthesis of Indoles via a Pd-Catalyzed C-N Ring Formation
  • 07/24/2014Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
  • 04/02/2014Constellation Pharmaceuticals will give a presentation on EZH2 and exhibit posters on EZH2 and BET at the AACR Annual Meeting, April 5-9 in San Diego, CA.
  • 01/14/2014Discovery and optimization of tetramethylpiperidinyl benzamides as inhibitors of EZH2
  • 11/06/2013Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth
  • 06/16/2013Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors
  • 10/04/2011Targeting MYC dependence in cancer by inhibiting BET bromodomains

Constellation Pharmaceuticals, Inc.
215 First Street, Suite 200
Cambridge, MA 02142

For Media Inquiries
https://www.morphosys.com/media

For General Inquires
To request additional information please use:
[email protected]
Phone: (617) 714-0555
Fax: (617) 577-0472

215 First Street, Suite 200
Cambridge, MA 02142
Contact Constellation

  • Facebook
  • Twitter
  • LinkedIn
  • About
    • Overview
    • Team
    • Contact
  • Our Science
    • About Epigenetics
    • Our Approach
    • Therapeutic Applications
  • Our Programs
    • Pipeline
    • BET
    • EZH2
    • LSD1
    • Preclinical
    • Expanded Access
    • Publications
  • Careers
    • Company Culture
    • Core Values
    • Benefits
    • Join Us
  • Investors & Media
    • Investor Overview
    • Stock Information
    • News & Events
    • Financial Information
    • Corporate Governance
    • Investor Resources

© Constellation Pharmaceuticals. All Rights Reserved.

  • Terms of Use / Privacy Policy
We use cookies to improve user experience, and analyze website traffic. For these reasons, we may share your site usage data with our analytics partners. By clicking “OK” you consent to our use of cookies and similiar technologies described in our Privacy Policy.OKPrivacy Policy